Patient's question:
Hello expert, I gave birth to my daughter last month, but she was diagnosed with neonatal hypoglycemia right after birth. I heard that all newborns with hypoglycemia will develop cerebral palsy later in life, is that correct? Also, could you please tell me the causes of neonatal hypoglycemia and whether it is due to genetic factors from my husband and me?Doctor's answer:
Neonatal hypoglycemia is a common condition in the neonatal period, frequently occurring in premature infants, small for gestational age infants, infants of diabetic mothers, and neonates with hypoxia, asphyxia, hardening syndrome, and sepsis. The incidence of hypoglycemia in full-term infants is 1% to 5%, while it can reach 15% to 25% in low birth weight infants and approximately 20% to 30% in neonatal asphyxia. Persistent or recurrent hypoglycemia can lead to severe central nervous system damage, causing energy metabolism disorders, brain cell swelling, softening, and necrosis, resulting in clinical manifestations such as intellectual disability and cerebral palsy. Hyperglycemia is primarily caused by iatrogenic factors, including diuresis, dehydration, shock, and intracranial hemorrhage, and can also lead to brain damage. Therefore, it is crucial for clinicians to pay attention to glucose monitoring to prevent hypoglycemia, achieve early diagnosis, and timely treatment to reduce the incidence and minimize brain damage.### Etiology of Hypoglycemia
1. Transient Hypoglycemia
- Reduced Glucose Production: Occurs during asphyxia, hunger, neonatal sepsis, cold injury, and preterm infants.
- Increased Glucose Consumption: Due to transient insulin excess, seen in infants of diabetic mothers, neonatal hemolytic disease, Beckwith syndrome, and maternal glucose infusion.
2. Persistent or Recurrent Hypoglycemia
- Persistent Insulin Excess: Includes islet cell hyperplasia, islet cell adenomas, and other causes of insulin excess.
- Reduced Glucose Production: Due to hormonal deficiencies (e.g., diabetes mellitus, congenital hypopituitarism) or congenital metabolic defects (e.g., amino acid metabolism disorders like maple syrup urine disease, and glycolytic disorders like galactosemia, glycogen storage disease type I).
3. Iatrogenic Hypoglycemia
Rapid glucose infusion may stimulate endogenous insulin secretion in neonates, potentially leading to reactive hypoglycemia upon abrupt cessation. Therefore, for neonates, especially low birth weight infants, glucose infusion should be gradually reduced and discontinued to avoid reactive hypoglycemia.
### Etiology of Hyperglycemia
1. Parenteral Nutrition: Exogenous glucose infusion fails to suppress endogenous glucose production.
2. Use of Adrenal Corticosteroids in Neonates:
3. Iatrogenic Hyperglycemia: Excessive glucose administration to neonates, high concentrations, or intolerance.
4. Neonatal Asphyxia: Release of catecholamines and glucagon reduces insulin levels or impairs islet endocrine cell function, often followed by hypoglycemia after hyperglycemia.
5. Transient Diabetes: May be due to delayed β-cell maturation.
6. True Diabetes: Rare in neonates.
### Pathogenesis
Glucose is the sole energy source for the central nervous system in neonates, but brain glycogen stores are minimal, yet energy demands are high. Neonates have active metabolism, with brain cells accounting for 13% of total body weight (compared to 2% in adults), requiring relatively more glucose. Hypoglycemia impairs brain cell metabolism, reducing ATP production and directly affecting Na+-K+-ATPase, leading to brain cell swelling, degeneration, and necrosis. Recurrent episodes exacerbate brain damage. Sensitivity to hypoglycemia varies across nervous system regions, with symptoms appearing in the following order: cerebral cortex, cerebellum, and subcortical centers (hypothalamus, motor and sensory as well as autonomic nerve centers, basal ganglia, etc.). Severe cases may cause brainstem dysfunction, resulting in sudden death.
Hyperglycemia causes plasma hyperosmolarity, extracellular fluid leakage, cerebral vasodilation, increased blood volume, and cerebral cell dehydration. Severe cases may lead to intracranial hemorrhage. Hyperglycemia can also cause osmotic diuresis, significant fluid and electrolyte loss, dehydration, and shock.
### Clinical Manifestations
1. Hypoglycemia:
- Asymptomatic or Atypical: Some neonates show no symptoms, while others may exhibit lethargy, weak crying, poor feeding and sucking, hypotonia, pallor, hypothermia, irregular breathing, pauses, or cyanosis. Severe cases may present with tremors, seizures, or coma, typically occurring within 1–2 days of birth. Diagnosis is confirmed through glucose monitoring.
2. Hyperglycemia:
- Early or Mild Cases: Asymptomatic. Severe cases may show polydipsia, polyuria, weight loss, sunken eyes, dehydration, or shock, and may also present with seizures or intracranial hemorrhage.
### Diagnostic Criteria
1. Hypoglycemia:
- Traditional diagnosis: Whole blood glucose < 2.22 mmol/L (40 mg/dL). Ogata ES proposed plasma glucose < 40 mg/dL as the definition, with plasma glucose levels 10%–15% higher than whole blood. In China, the current standard is whole blood glucose < 2.22 mmol/L (40 mg/dL).
2. Hyperglycemia:
- Whole blood glucose ≥ 7 mmol/L (135 mg/dL).
3. Inappropriate Insulin Levels:
- Serum insulin level (μU/L) / blood glucose level (mmol/L) > 0.3.
### Glucose Monitoring Methods
Common methods include paper strip testing, micro-blood glucose meters using heel pricks, and venous blood monitoring. Early and timed monitoring is recommended at birth (1, 3, 6, 9, 12, and 24 hours) or upon admission. However, many grassroots hospitals lack the resources for glucose monitoring. Tianjin Children’s Hospital proposed using a computer to analyze intrinsic hypoglycemia risk factors (gestational age, weight, birth weight, infection, and hypoxia) and established the discriminant formula:
Y = 0.18295X? - 0.90382X? - 0.0519X? + 5.6895X? + 5.10437X?. Neonates with a score Y ≥ -33.80474 are classified as high-risk for hypoglycemia, requiring preventive measures. In a study of 310 neonates, the accuracy was high with a misclassification rate of 2.42%, making it suitable for clinical use.
### History
- Maternal diabetes, history of pregnancy-induced hypertension, neonatal asphyxia, preterm birth, small for gestational age, severe infection, hardening syndrome, hemolysis, polycythemia; history of parenteral nutrition or theophylline use.
### Treatment Measures
1. Hypoglycemia:
- Symptomatic or Asymptomatic Hypoglycemia:
- Oral: 10% glucose 5–10 mL/kg every 2–3 hours.
- Intravenous: 10% glucose at a rate of 6–8 mg/(kg·min), with blood glucose checked every 4–6 hours to adjust the infusion rate. After 24 hours, discontinue intravenous infusion and switch to oral glucose solution for 1 day. Feeding with mother’s milk or formula is encouraged if possible.
- Symptomatic Hypoglycemia:
- Slow intravenous injection of 25% glucose 2–4 mL/kg at a rate of 1 mL/min. Continue with 10%–12% glucose infusion at 8–10 mg/(kg·min), with regular blood glucose monitoring. Once stable for 24–48 hours, switch to 5% glucose and gradually reduce the dose over 2–3 days. Early initiation of breastfeeding or formula feeding is recommended.
- Persistent or Severe Hypoglycemia:
- If blood glucose remains unstable after 3 days of treatment, add hydrocortisone 5 mg/kg/day for 2–3 days via intravenous infusion.
- Glucagon 0.03 mg/kg can be administered intramuscularly every 6–12 hours.
- For hyperinsulinemia, epinephrine (initially 1:1000, 0.01 mg/kg intradermally) can be used if effective. Alternatively, epinephrine diluted in 25% glucose (1:200, 0.005–0.01 mL/kg every 6 hours) or phenylephrine (0.05 mg/kg orally every 3 hours) for infants of diabetic mothers.
- Diazoxide (to inhibit insulin release) can be administered at 10–15 mg/kg/day in divided doses.
- Pancreatic resection may be required for islet hyperplasia or adenomas.
- For galactosemia, lactose-containing foods must be avoided, and soy-based formula used instead.
2. Hyperglycemia:
- Primarily iatrogenic.
- Treatment: Reduce glucose intake (less than 812 g/kg/day), especially for premature infants, starting with 5% glucose and maintaining an infusion rate of 4–6 mg/(kg·min).
- If blood glucose > 16.8 mmol/L (300 mg/dL) with positive urine glucose or persistent symptoms despite fluid rate adjustment, insulin supplementation (0.1–0.2 U/kg subcutaneously) may be needed, repeated every 6–12 hours if necessary.
- Correct dehydration and electrolyte imbalances. Monitor blood glucose when using theophylline or corticosteroids.
- For transient hyperglycemia, treatment is usually unnecessary. For severe hyperglycemia or symptoms, immediate subcutaneous insulin (0.2 U/kg) followed by continuous intravenous infusion (1–3 U/kg/day) for 2–2 days, with fluid replacement at 1/4–1/5 normal saline.
### Prevention
1. Monitoring: Neonates at risk of hypoglycemia should have blood glucose checked at 3, 6, 9, 12, and 24 hours to detect hypoglycemia or hyperglycemia early.
2. Feeding: Early feeding is crucial for low birth weight and high-risk infants, starting with glucose solution or milk at 2–4 hours of life. For those unable to feed orally or via nasogastric tube, intravenous glucose should be administered.
3. Parenteral Nutrition: Ensure adequate amino acids and lipid supplementation when providing calories, avoiding excessively high glucose concentrations.
4. Glucose Infusion: For high-risk and premature infants, control glucose infusion rate (not exceeding 8 mg/(kg·min)) and monitor blood glucose. If levels rise, immediately reduce infusion rate and concentration but avoid abrupt cessation to prevent reactive hypoglycemia.